Hybrid Event: Real-world insights on COVID-19 vaccine effectiveness and infection risk factors from CanPath’s SUPPORT-Canada study
About the event:
Dr. Victoria Kirsh presented an in-depth analysis of COVID-19 vaccine effectiveness based on real-world data from the SUrveying Prospective Population cOhorts for COVID-19 pRevalence and ouTcomes in Canada (SUPPORT-Canada) study. Check out the recording of the event to discover the latest findings derived from our three-year study including the answers to critical questions such as:
- How many COVID-19 diagnoses were among those who did not suspect they were infected?
- What is the effectiveness of full or booster vaccination in preventing Omicron infection?
- How protective is prior infection against reinfection?
About the presenter:
Dr. Victoria Kirsh is the Scientific Associate at the Ontario Health Study, one of CanPath’s regional cohorts. Dr. Kirsh completed a Ph.D. in Epidemiology from Yale University, an M.Sc. in Epidemiology from the University of Toronto and a B.Sc. in Microbiology and Immunology from McGill University. She completed a fellowship at the U.S. National Cancer Institute, Division of Cancer Epidemiology and Genetics. She worked as an Assistant Professor at the Dalla Lana School of Public Health, University of Toronto, and as a Scientist at Cancer Care Ontario before joining the Ontario Health Study.
Acknowledgement:
The Canadian Partnership for Tomorrow’s Health (CanPath) research is only possible with the commitment of its research participants, its staff and its funders. The data and biosamples used in this research were made available by CanPath and the COVID-19 Immunity Task Force and Public Health Agency of Canada.